InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. A potential advantage of inhalation therapy is that it delivers medicine in the “first pass” to cardiac tissue, directly addressing affected regions of the heart. Inhaled routes of administration offer rapid effect, fast clearance and reduced exposure at lower doses and the potential to effectively balance efficacy and safety.
Our lead product under development is an inhaled therapy to treat acute episodes of paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs and devices with a long history of efficacy and safety in a new dosing paradigm.
We have a highly experienced, passionate team with a strong track record of development. We are also supported by a world-class group of experts and advisors.